BRIEF—F-star Therapeutics inks license deal with Takeda

F-star Therapeutics, a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that it has entered into a license agreement with Japan’s Takeda.

Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-star’s proprietary Fcab and mAb2 platforms.

Takeda will be responsible for all research, development, and commercialization activities under the agreement.

F-star will receive an upfront license fee of $1 million.

F-star is also eligible to receive future development and commercialization milestone payments up to approximately $40 million over the course of the agreement if all milestones are achieved, plus single-digit percentage royalties on annual net sales.